AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Cancer Education
Explore expert insights on the fundamentals of cancer, including how it develops, key risk factors, prevention strategies, and treatment options. This section also highlights cancer awareness months and related observance days and weeks. Commentaries from our network of oncology professionals shed light on critical issues that require greater attention across the cancer care and research continuum.
Attorney Henry T. Greely on Navigating Ethical Challenges in Precision Oncology
By The Cancer News Team
A multidisciplinary panel led by Stanford ethicist Henry T. Greely, JD, examines the ethical challenges of precision oncology, including informed consent, access disparities, privacy concerns, and real-world clinical decision-making.
Attorney Henry T. Greely on Navigating Ethical Challenges in Precision Oncology
By The Cancer News Team
A multidisciplinary panel led by Stanford ethicist Henry T. Greely, JD, examines the ethical challenges of precision oncology, including informed consent, access disparities, privacy concerns, and real-world clinical decision-making.
Attorney Henry T. Greely on Navigating Ethical Challenges in Precision Oncology
By The Cancer News Team
A multidisciplinary panel led by Stanford ethicist Henry T. Greely, JD, examines the ethical challenges of precision oncology, including informed consent, access disparities, privacy concerns, and real-world clinical decision-making.
Liquid Biopsy in Oncology: What Clinicians Are Actually Saying
By The Cancer News Team
A multidisciplinary panel of oncology experts discusses real-world use of liquid biopsy, comparing it with tissue biopsy and exploring clonal hematopoiesis, tumor-informed assays, minimal residual disease testing, and circulating tumor DNA.
Liquid Biopsy in Oncology: What Clinicians Are Actually Saying
By The Cancer News Team
A multidisciplinary panel of oncology experts discusses real-world use of liquid biopsy, comparing it with tissue biopsy and exploring clonal hematopoiesis, tumor-informed assays, minimal residual disease testing, and circulating tumor DNA.
Liquid Biopsy in Oncology: What Clinicians Are Actually Saying
By The Cancer News Team
A multidisciplinary panel of oncology experts discusses real-world use of liquid biopsy, comparing it with tissue biopsy and exploring clonal hematopoiesis, tumor-informed assays, minimal residual disease testing, and circulating tumor DNA.
Highlights of ASCO Gastrointestinal Cancer Symposium 2026: From Bench to Bedside
By Dr. Meghana Singh; Ibrahim Halil Sahin, MD
Key clinical trial highlights from ASCO GI 2026, covering practice-changing data in gastric, colorectal, pancreatic, and liver cancers, including HERIZON GEA-01, ILLUSTRO, COMMIT II, and BREAKWATER.
Highlights of ASCO Gastrointestinal Cancer Symposium 2026: From Bench to Bedside
By Dr. Meghana Singh; Ibrahim Halil Sahin, MD
Key clinical trial highlights from ASCO GI 2026, covering practice-changing data in gastric, colorectal, pancreatic, and liver cancers, including HERIZON GEA-01, ILLUSTRO, COMMIT II, and BREAKWATER.
Highlights of ASCO Gastrointestinal Cancer Symposium 2026: From Bench to Bedside
By Dr. Meghana Singh; Ibrahim Halil Sahin, MD
Key clinical trial highlights from ASCO GI 2026, covering practice-changing data in gastric, colorectal, pancreatic, and liver cancers, including HERIZON GEA-01, ILLUSTRO, COMMIT II, and BREAKWATER.
Dr. Matthew H. Schwede’s Insights on Advances in Cellular Therapy
By The Cancer News Team
An expert overview of key advances in cellular therapy presented by Dr. Matthew H. Schwede at the Best of Hematology & Breast Cancer 2026 conference, focusing on CAR T innovation, rapid manufacturing, in vivo approaches, and emerging treatment strategies.
Dr. Matthew H. Schwede’s Insights on Advances in Cellular Therapy
By The Cancer News Team
An expert overview of key advances in cellular therapy presented by Dr. Matthew H. Schwede at the Best of Hematology & Breast Cancer 2026 conference, focusing on CAR T innovation, rapid manufacturing, in vivo approaches, and emerging treatment strategies.
Dr. Matthew H. Schwede’s Insights on Advances in Cellular Therapy
By The Cancer News Team
An expert overview of key advances in cellular therapy presented by Dr. Matthew H. Schwede at the Best of Hematology & Breast Cancer 2026 conference, focusing on CAR T innovation, rapid manufacturing, in vivo approaches, and emerging treatment strategies.
What Are Doctors Saying About Cancer Prevention? Insights from Leading Oncologists
By The Cancer News Team
Leading oncologists discuss evidence-based cancer prevention strategies, treatment-related weight gain, and major gaps in survivorship care, based on insights shared at a major oncology conference.
What Are Doctors Saying About Cancer Prevention? Insights from Leading Oncologists
By The Cancer News Team
Leading oncologists discuss evidence-based cancer prevention strategies, treatment-related weight gain, and major gaps in survivorship care, based on insights shared at a major oncology conference.
What Are Doctors Saying About Cancer Prevention? Insights from Leading Oncologists
By The Cancer News Team
Leading oncologists discuss evidence-based cancer prevention strategies, treatment-related weight gain, and major gaps in survivorship care, based on insights shared at a major oncology conference.
Dr. Bart L Scott on Treatment Approaches in Newly Diagnosed Acute Myeloid Leukemia
By The Cancer News Team
Summary of Dr. Bart L. Scott’s presentation on first-line treatment strategies for newly diagnosed acute myeloid leukemia, highlighting azacitidine–venetoclax, the Paradigm trial, and patient-centered decision-making.
Dr. Bart L Scott on Treatment Approaches in Newly Diagnosed Acute Myeloid Leukemia
By The Cancer News Team
Summary of Dr. Bart L. Scott’s presentation on first-line treatment strategies for newly diagnosed acute myeloid leukemia, highlighting azacitidine–venetoclax, the Paradigm trial, and patient-centered decision-making.
Dr. Bart L Scott on Treatment Approaches in Newly Diagnosed Acute Myeloid Leukemia
By The Cancer News Team
Summary of Dr. Bart L. Scott’s presentation on first-line treatment strategies for newly diagnosed acute myeloid leukemia, highlighting azacitidine–venetoclax, the Paradigm trial, and patient-centered decision-making.
How Medical Oncologists Select Targeted Therapies for Breast Cancer ESR1 and Pancreatic MTAP Mutations
By The Cancer News Team
Expert tumor board discussion from the Precision Oncology Summit on ESR1-mutant breast cancer and MTAP-deleted pancreatic cancer, highlighting real-world cases, oral SERDs, PRMT5 inhibitors, and biomarker-driven treatment decisions.
How Medical Oncologists Select Targeted Therapies for Breast Cancer ESR1 and Pancreatic MTAP Mutations
By The Cancer News Team
Expert tumor board discussion from the Precision Oncology Summit on ESR1-mutant breast cancer and MTAP-deleted pancreatic cancer, highlighting real-world cases, oral SERDs, PRMT5 inhibitors, and biomarker-driven treatment decisions.
How Medical Oncologists Select Targeted Therapies for Breast Cancer ESR1 and Pancreatic MTAP Mutations
By The Cancer News Team
Expert tumor board discussion from the Precision Oncology Summit on ESR1-mutant breast cancer and MTAP-deleted pancreatic cancer, highlighting real-world cases, oral SERDs, PRMT5 inhibitors, and biomarker-driven treatment decisions.
New Study Offers Hope for Better Treatment Strategies: Understanding Blast Phase Chronic Myeloid Leukemia
By Akriti Jain, MD
A leukemia specialist discusses new insights from a multicenter U.S. study on blast phase chronic myeloid leukemia, highlighting treatment patterns, outcomes, and the critical role of TKIs and transplantation.
New Study Offers Hope for Better Treatment Strategies: Understanding Blast Phase Chronic Myeloid Leukemia
By Akriti Jain, MD
A leukemia specialist discusses new insights from a multicenter U.S. study on blast phase chronic myeloid leukemia, highlighting treatment patterns, outcomes, and the critical role of TKIs and transplantation.
New Study Offers Hope for Better Treatment Strategies: Understanding Blast Phase Chronic Myeloid Leukemia
By Akriti Jain, MD
A leukemia specialist discusses new insights from a multicenter U.S. study on blast phase chronic myeloid leukemia, highlighting treatment patterns, outcomes, and the critical role of TKIs and transplantation.
What Types of Cancer Cause Low Hemoglobin?
By Chandra Lalita Kakarala, MD
An expert overview of how different cancers cause low hemoglobin, explaining anemia mechanisms, symptoms, diagnosis, and treatment in cancer patients.
What Types of Cancer Cause Low Hemoglobin?
By Chandra Lalita Kakarala, MD
An expert overview of how different cancers cause low hemoglobin, explaining anemia mechanisms, symptoms, diagnosis, and treatment in cancer patients.
What Types of Cancer Cause Low Hemoglobin?
By Chandra Lalita Kakarala, MD
An expert overview of how different cancers cause low hemoglobin, explaining anemia mechanisms, symptoms, diagnosis, and treatment in cancer patients.
2025 Oncology Year in Review: Breakthrough Cancer Treatments and Research
By Aishat Motolani, PhD
A comprehensive 2025 oncology year in review exploring breakthroughs in cancer treatment, AI in oncology, immunotherapy approvals, liquid biopsy debates, mRNA vaccines, and global cancer health equity.
2025 Oncology Year in Review: Breakthrough Cancer Treatments and Research
By Aishat Motolani, PhD
A comprehensive 2025 oncology year in review exploring breakthroughs in cancer treatment, AI in oncology, immunotherapy approvals, liquid biopsy debates, mRNA vaccines, and global cancer health equity.
2025 Oncology Year in Review: Breakthrough Cancer Treatments and Research
By Aishat Motolani, PhD
A comprehensive 2025 oncology year in review exploring breakthroughs in cancer treatment, AI in oncology, immunotherapy approvals, liquid biopsy debates, mRNA vaccines, and global cancer health equity.